Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM - PACE-CME

Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Understanding the etiology of HCM and pathways for intervention
Understanding the etiology of HCM and pathways for intervention
MinuteCE®
Understanding the etiology of HCM and pathways for intervention
0.75 program credits
- Roberto Barriales-Villa, MD, PhD
0.75 program credits
Recommendations on the management of HCM in guidelines: European vs. American views
Recommendations on the management of HCM in guidelines: European vs. American views
MinuteCE®
Recommendations on the management of HCM in guidelines: European vs. American views
0.75 program credits
- Roberto Barriales-Villa, MD, PhD
- Ahmad Masri, MD, MS
0.75 program credits
Myosin inhibitors: recent clinical data and applications in HCM and HF
Myosin inhibitors: recent clinical data and applications in HCM and HF
MinuteCE®
Myosin inhibitors: recent clinical data and applications in HCM and HF
0.75 program credits
- Caroline Coats, MD
0.75 program credits
Epidemiology and clinical features of HCM
Epidemiology and clinical features of HCM
MinuteCE®
Epidemiology and clinical features of HCM
0.75 program credits
- Perry Elliott, MD
0.75 program credits